Carboviram is a tetrapeptide-based epoxy skeleton proteasome inhibitor irreversibly bound to the 20S proteasome containing threonine at the N-terminal active site, and the 26S protease in vivo proteolytic core particles. Carfilzomib has anti-proliferative and apoptotic activity in vitro in solid and hematopoietic granulocytes. In animals, carfilzomib inhibits proteasome activity in blood and tissue and delays tumor growth in multiple myeloma, hematology, and solid tumor models.
Indications and uses
Kyprolis is a proteasome inhibitor for the treatment of patients with multiple myeloma who have received at least two previous treatments including bortezomib and an immunomodulatory agent and has confirmed the progress of the disease or the last treatment completed within 60 days. Approval is based on response rate. Has not yet proven clinical benefits, such as survival or symptom improvement.
(1) 2 to 10 minutes per week for 2 consecutive weeks for 3 weeks (1, 2, 8, 9, 15, and 16 days) followed by 12-day rest periods (days 17 to 28).
(2) Recommended course of treatment 1 dose is 20 mg / m2 / day and if tolerated increase the dose of the second course of treatment and subsequent treatment dose to 27 mg / m2 / day.
(3) before and after hydration patients.
(4) Pretreatment with dexamethasone prior to all first course doses. During the first course of treatment, and if the infusion reaction occurs or occurs again.
(5) Administration according to toxicity.
(1) Cardiac adverse reactions include heart failure and ischemia: monitoring of cardiac complications. Timely treatment and suspension of Kyprolis.
(2) pulmonary hypertension: if suspected to stop the administration.
(3) Pulmonary complications: Surveillance and immediate treatment of dyspnea, interruption of Kyprolis until the symptoms have been resolved or restored to baseline.
(4) infusion reaction: pre-administration with dexamethasone prevention.
(5) advise the patient if the symptoms immediately look for medical attention.
(6) thrombocytopenia: monitoring of platelet counts; when clinically instructed to reduce or discontinue administration.
(8) fetal fetal toxicity: Kyprolis can cause fetal harm. Fertility women should be treated as a pregnancy should be avoided.
The most frequently reported adverse events (incidence ≥ 30%) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever.
Special crowd used
Patients are dialysis: After dialysis operation, given Kyprolis.
Unopened vials should be stored in the refrigerator (2°C to8 °C;36 °Fto46°F). Keep in the original packaging protected from light.